Published on 8 Oct 2024 on GuruFocus.com · via Yahoo Finance
Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
Overview of the Recent Transaction
On September 30, 2024, Morgan Stanley executed a significant transaction involving the sale of 192,770 shares in Replimune Group Inc (NASDAQ:REPL), a clinical-stage biotechnology company. This move reduced Morgan Stanley's holding by 11.11%, leaving the firm with a total of 1,542,884 shares. Despite the reduction, Morgan Stanley maintains a 2.30% position in REPL, reflecting a strategic adjustment rather than a complete exit. The shares were traded at a price of $10.96 each, marking a notable shift in the firm's investment strategy.
Profile of Morgan Stanley